Last reviewed 2026-05-24 · How we verify

Glucamethacin (GLUCAMETACIN)

Phase 2 active Small molecule ✓ Verified May 2026

Glucamethacin (generic name: GLUCAMETACIN) is a glucametacin drug. It is currently in Phase 2 development.

Glucametacin is thought to work by inhibiting the production of prostaglandins, which are hormone-like substances that contribute to inflammation and pain.

Glucamethacin is a small molecule. It has several synonyms, including GLUCAMETACIN, GLUCAMETACINA, GLUCAMETACINE, GLUCAMETAN, and GLUCAMETHACIN.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GLUCAMETACIN
Drug class	glucametacin
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Imagine your body's inflammation response like a fire. Prostaglandins are like the fuel that keeps the fire burning. Glucametacin is thought to reduce the amount of fuel available, thereby reducing the intensity of the inflammation and pain.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Glucamethacin CI brief — competitive landscape report
Glucamethacin updates RSS · CI watch RSS

Frequently asked questions about Glucamethacin

What is Glucamethacin?

Glucamethacin (GLUCAMETACIN) is a glucametacin drug.

How does Glucamethacin work?

Glucametacin is thought to work by inhibiting the production of prostaglandins, which are hormone-like substances that contribute to inflammation and pain.

What is the generic name of Glucamethacin?

GLUCAMETACIN is the generic (nonproprietary) name of Glucamethacin.

What drug class is Glucamethacin in?

Glucamethacin belongs to the glucametacin class. See all glucametacin drugs at /class/glucametacin.

What development phase is Glucamethacin in?

Glucamethacin is in Phase 2.

Drug class: All glucametacin drugs
Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing